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Treatment-resistant schizophrenia (TRS) continues to be a challenge. It was related to
different factors, including alterations in the activity of brain dopaminergic system, which
could be influenced by the dopamine-degrading enzyme, catechol-O-methyltransferase
(COMT). Variants of the COMT gene have been extensively studied as risk factors
for schizophrenia; however, their association with TRS has been poorly investigated.
The aim of the present study was to determine the haplotypic and genotypic
association of COMT rs4680 and rs4818 polymorphisms with the presence of TRS.
Overall, 931 Caucasian patients diagnosed with schizophrenia (386 females and 545
males) were included, while 270 participants met the criteria for TRS. In males, no
significant haplotypic and genotypic associations between COMT rs4680 and rs4818
polymorphisms and TRS were detected. However, genotypic analyses demonstrated
higher frequency of COMT rs4680 AA genotype carriers compared to G-allele carriers
(p = 0.033) and higher frequency of COMT rs4818 CC genotype carriers than G-allele
carriers (p = 0.014) in females with TRS. Haplotype analyses confirmed that the
presence of the G allele in females was associated with lower risk of TRS. In women with
TRS, the high activity G-G/G-G haplotype was rare, while carriers of other haplotypes
were overrepresented (p = 0.009). Such associations of COMT rs4680 and rs4818 high-
activity (G variants), as well as G-G/G-G haplotype, with the lower risk of TRS in females,
but not in males, suggest significant, but sex-specific influence of COMT variants on the
development of treatment-resistance in patients with schizophrenia. However, due to
relatively low number of females, those findings require replication in a larger sample.
Keywords: treatment-resistant schizophrenia, COMT rs4680 polymorphism, COMT rs4818 polymorphism, COMT
rs4680 and rs4818 haplotype, sex-specific association
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INTRODUCTION
Schizophrenia is a severe psychiatric disorder. Antipsychotics
are the first-line agents in the treatment of schizophrenia, but
the clinical response is highly variable. Between 23% (Demjaha
et al., 2017) and 47% (Vlatkovic et al., 2018) of patients met
the criteria for treatment-resistant schizophrenia (TRS), although
the definition has varied across different studies (Howes et al.,
2017). In spite of more than 60 years of the widespread use of
antipsychotics, TRS continues to present an enormous challenge
(Šagud, 2015; Lally et al., 2016). While altered dopaminergic
function is the main feature of schizophrenia (Lally et al.,
2016; Nedic Erjavec et al., 2017; Nikolac Perkovic et al., 2017;
Pruessner et al., 2017), patients with TRS might have distinct
dopamine changes, such as lower dopamine synthesis capacity in
the striatum (Kim et al., 2017), lower density of dopaminergic
synapses in the caudate nucleus (Roberts et al., 2009), and a
decrease in the dopamine transporter protein expression (Purves-
Tyson et al., 2017), compared to patients who responded to
antipsychotics. There is an urgent need to distinguish TRS from
non-TRS using genetic or other markers (Šagud, 2015; Lally et al.,
2016; Gillespie et al., 2017) as early as possible, in order to provide
the best possible treatment for an individual patient.
Catechol-O-methyltransferase (COMT) is an important
enzyme that degrades catecholamines including dopamine.
COMT regulates dopamine availability primarily in the
prefrontal cortex (PFC), where the presence of dopamine
transporters is scarce (Bilder et al., 2004). Variants of the
COMT gene have been extensively studied as risk factors for
schizophrenia (Egan et al., 2001). Among various polymorphisms
of the COMT gene, rs4680 and rs4818 significantly affect COMT
activity and therefore prefrontal dopamine levels and function.
The rs4680 (A > G substitution) or Val108/158Met is the
most common functional COMT polymorphism in which a
G/A substitution results in valine (Val) to methionine (Met)
replacement at codon 158 for membrane-bound (MB) COMT,
and at codon 108 for the soluble (S) COMT. The Met (A) variant
has been associated with a lower thermostability, fourfold lower
functional enzyme activity (Lachman et al., 1996), lower protein
expression (Chen et al., 2004), and higher dopamine activity
compared to Val (G) variant. Previously observed association
between COMT rs4680 and schizophrenia (Egan et al., 2001;
González-Castro et al., 2016) was not confirmed in a meta-
analysis (Munafo et al., 2005), or in a cohort with large number
of ethnically homogeneous Caucasians in our previous study
(Nikolac et al., 2013). Another frequently studied polymorphism
of the COMT gene is a synonymous polymorphism rs4818,
with a C/G substitution (Leu/Leu) at codon 86 of S-COMT
or at codon 136 of MB-COMT (Roussos et al., 2008). The
G variant of the COMT rs4818 polymorphism is associated
with greater COMT activity and therefore lower prefrontal
dopamine activity (Roussos et al., 2008). It has been reported
that COMT rs4818 is responsible for the larger variation in the
COMT activity than the COMT rs4680 polymorphism (Nackley
et al., 2006). Some studies demonstrated that COMT rs4818
polymorphism was not associated with schizophrenia (Chen
C.Y. et al., 2011; Li et al., 2012); however, it is transmitted
together with COMT rs4680 polymorphism in a haploblock
(Hirasawa-Fujita et al., 2018). Contradictory findings exist for
the association of COMT haplotypes and schizophrenia or its
symptoms (Chen C.Y. et al., 2011; Li et al., 2012). Haplotype
including COMT rs4818 G allele (with rs740603/G allele)
was linked to negative symptoms of schizophrenia (Li et al.,
2012). However, no significant association of several functional
COMT polymorphisms and haplotypes with schizophrenia
or with psychopathological symptoms was found (Chen C.Y.
et al., 2011). Moreover, there were no differences between
patients with and without TRS in the whole-blood gene
expression of 13 genes, including COMT gene (Moretti et al.,
2018).
Despite a considerable amount of research on the association
of COMT rs4680 variants with the response to antipsychotics
(Huang et al., 2016), only four studies addressed this COMT
polymorphism in relation to TRS (Inada et al., 2003; Bosia
et al., 2015; Terzic´ et al., 2016; Rajagopal et al., 2018). These
studies yielded inconsistent results, had relatively small sample
sizes and the data were not separately analyzed for males
and females, although sex-specific associations with COMT
rs4680 have been reported. For example, the overexpression
of the rs4680 GG genotype was found in Spanish males with
schizophrenia compared to general population, with no such
differences in females (Hoenicka et al., 2010). The presence of
one or two A allele in the COMT rs4680 elevated the risk of
violence in male, but not female patients with schizophrenia
(Singh et al., 2012). On the other hand, when COMT rs4680
was investigated in Slovenian suicide victims, the AA genotype
was more common in the group of control males than in
males who committed suicide, and in the control males versus
males who committed suicide with violent methods, while
again no differences were observed among females (Pivac
et al., 2011). The interpretation of the influence of this COMT
functional polymorphism in psychiatric disorders is therefore
complicated by sex-, but also by ethnic-related differences in
allele distributions. Whereas Caucasians had similar frequencies
of the A and G alleles, the G allele was more common
in Asian and other populations (Palmatier et al., 1999). In
contrast to these findings, the A allele was associated with
bipolar disorder in Asian but not in Caucasian subjects
(Taylor, 2018). Moreover, in the meta-analysis of case-control
studies, the presence of the G allele of the COMT rs4680 was
associated with schizophrenia in Caucasian, but not in Asian
population, although the data were not analyzed by gender
(González-Castro et al., 2016). In addition, only a few studies
investigated COMT rs4818 polymorphism and the response to
antipsychotics (Gupta et al., 2009; Xu et al., 2015; Shi et al.,
2017).
Since there is inconclusive or insufficient evidence on the
association of COMT rs4680 and rs4818 polymorphisms with
TRS, especially regarding gender and ethnic differences, the
aim of this study was to evaluate genotypic and haplotypic
association of the COMT rs4680 and rs4818 and TRS in ethnically
homogeneous Caucasian subjects of both sexes. Our hypothesis
was that patients with TRS have the overrepresentation of rs4680
A allele, as well as rs4818 C allele, compared to non-TRS patients,
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and that the observed associations with COMT are gender-
specific.
MATERIALS AND METHODS
Subjects
This cross-sectional study included 931 biologically unrelated
Caucasian patients with schizophrenia, 585 males and 386
females, who gave their consent to participate and met the
inclusion criteria, and were considered eligible. Subjects were
recruited from the University Hospital Centre Zagreb, University
Psychiatric Hospital Vrapce, Zagreb, and Neuropsychiatric
Hospital Dr. Ivan Barbot, Popovaca, Croatia. Inclusion criteria
were in- and out-patients aged 18–65 years, diagnosed with
schizophrenia for at least 5 years. Diagnosis was confirmed
using the Structured Clinical Interview (SCID; First et al., 1995)
based on the DSM-IV criteria [American Psychiatric Association
[APA], 1994]. Exclusion criteria were intellectual disabilities,
patients with first-episode psychosis and/or no previous
treatment with antipsychotics, substance abuse and dependence
in the previous three months, any comorbid severe somatic or
neurological disorder and patients who had no available detailed
medical records with complete psychiatric medication history.
After inclusion, all patients underwent complete diagnostic
evaluation. Clinical Global Impression-Severity (CGI-S) scale
was used to assess the severity of patients’ clinical condition
(Guy, 1976). Patients were evaluated using structured interview
for the Positive and Negative Syndrome Scale (PANSS) including
the PANSS positive, PANSS negative and PANSS general
psychopathology subscale (Kay et al., 1987). Schizophrenic
patients were subdivided into 574 smokers (i.e., current smokers)
and 354 non-smokers (i.e., never smokers and former smokers),
whereas for three patients smoking status was not defined.
Besides nicotine dependence, no other co-morbid substance
abuse or dependence was present. All patients were Caucasians
of Croatian origin. The patients were treated with different
antipsychotic medication: olanzapine, either as monotherapy
or antipsychotic combination (5–20 mg/day), clozapine
(300–800 mg/day), risperidone (2–6 mg/day), fluphenazine
(5–15 mg/day), haloperidol (4–15 mg/day), promazine (400–
500 mg/day), alone or combined with benzodiazepines,
i.e., diazepam (2–10 mg/day). Mean dose of antipsychotic
medication, calculated into chlorpromazine equivalent doses,
was 309.5 ± 263.5 mg/day (range 50–1600 mg/day). Although
the concept of TRS is widely used, there is a lack of consensus
how to define it. In our study, patients were classified in TRS or
non-TRS group according to criteria proposed by Suzuki et al.
(2012), which refer to the failure of at least two antipsychotics,
given at ≥600 mg chlorpromazine equivalents (Inada and
Inagaki, 2015) for more than consecutive 6 weeks, assessed
retrospectively. Out of 931 patients, 270 of them met the
criteria for TRS and 661 were non-TRS patients. At the time
of assessment, psychiatrists were not aware of the genetic test
results. The study was approved by the Ethics Committees of
the University Hospital Centre Zagreb, University Psychiatric
Hospital Vrapce, and Neuropsychiatric Hospital Dr. Ivan
Barbot, Popovaca, Croatia, and was carried out in accordance
with the Helsinki declaration (1975), as revised in 1983.
All patients have signed informed consent prior to study
procedures.
Genotyping
The COMT rs4680 (assay ID: C_25746809_50) and rs4818
(assay ID: C_2538750_10) genotypes were determined using
DNA isolated from the blood samples with a salting out
method (Miller et al., 1988). Genotyping was performed
using the primers and probes from the TaqMan R© Drug
Metabolism Genotyping Assays (Applied Biosystems, Foster
City, CA, United States) on ABI Prism 7300 Real time
PCR System apparatus (Applied Biosystems, Foster City, CA,
United States), according to the procedures described by
Applied Biosystems. The 10 µL reaction volume contained
30–100 ng of DNA. Around 10% of randomly selected samples
were genotyped again as a quality control for genotyping
assays.
Statistical Analyses
Data were analyzed using Graph Prism version 7.00 (GraphPad
Software, Inc.). Data distribution normality was determined
with the Kolmogorov–Smirnov normality test. Due to the
lack of a normal distribution, Kruskal–Wallis analysis of
variance (ANOVA) and Dunn post hoc were used to assess
differences in age, chlorpromazine equivalent doses, PANSS
total, positive, negative, and general psychopathology scores
between different groups of patients. The Hardy–Weinberg
equilibrium (HWE) was determined using χ2-test (Rodriguez
et al., 2009). Smoking status, as well as genotype and
haplotype distributions, between male and female patients
with TRS and non-TRS, were also compared using χ2-test
(Rodriguez et al., 2009). To assess which category was a
major contributor to rejecting the null hypothesis, standardized
residuals (R; Field et al., 2012) were calculated. Haploview
software v. 4.2 (Barrett et al., 2005) was used to determine
LD pairwise values for COMT rs4818 and rs4680. Loci are
considered to be in linkage disequilibrium if D′ coefficient
is >0.80. Best-estimate haplotype pair for every patient was
assigned by PLINK v. 1.07 software using the expectation–
maximization algorithm (Purcell et al., 2007). Besides genotypic
and haplotypic analyses, additional genetic models (González-
Castro et al., 2016) were evaluated: dominant model (G carriers,
i.e., GG + GA vs. AA) and recessive model (A carriers,
i.e., GA + AA vs. GG) for the COMT rs4680, as well as
dominant model (C carriers, i.e., CC + CG vs. GG) and
recessive model (G carriers, i.e., GG + GC vs. CC) for
the COMT rs4818. For individual SNP analysis the p-value
(0.05/2 = 0.025) was corrected because two SNPs were compared
and the results were considered significant if p < 0.025.
G∗Power 3 Software (Faul et al., 2009) was used to determine
a priori sample size. For a χ2-test [with α = 0.025; with
expected small effect size = 0.2; power (1 − β) = 0.800],
the required sample size was N = 288 with df = 2; or
N = 238 for df = 1. For Kruskal–Wallis ANOVA, the p-value
(0.05/4 = 0.0375) was corrected because of four groups into
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α = 0.0375; with expected small effect size = 0.15; and power
(1 − β) = 0.800]; the required sample size was 528. As the
study included 931 participants, it had adequate sample size
and statistical power to detect significant differences among the
groups.
RESULTS
Clinical and Demographic Data
Treatment-resistance (TRS) differed significantly (χ2 = 69.694;
df = 1; p < 0.001) between male and female patients, since
males were more frequently treatment resistant (79.6%) than
females (20.4%), and the lowest number of female TRS patients
(R = 5.4) significantly contributed to this significance. Therefore,
in further analyses all TRS and non-TRS patients were subdivided
according to gender (Table 1).
Dunn post hoc analysis performed following Kruskal–Wallis
ANOVA confirmed significant difference (p < 0.001) in age,
chlorpromazine equivalent doses, PANSS total, positive, negative,
and general psychopathology scores between male and female
patients in TRS, as well as in non-TRS group. Moreover,
there were also significant differences (p < 0.001) between
male patients with TRS and non-TRS, as well as between
female patients with TRS and non-TRS, in chlorpromazine
equivalent doses, PANSS total, positive, negative, and general
psychopathology scores, but not in the age.
As shown in Table 1, the distribution of smokers and non-
smokers was also significantly different (p < 0.0001) between
male and female patients with TRS and non-TRS. Significantly
(R = 2.86) lower frequency of female non-smokers in non-TRS
group contributed to this difference. Males smoked more often
than females in both TRS (χ2 = 10.55; df = 1; p = 0.0012) and
no-TRS group (χ2 = 15.27; df = 1; p < 0.0001); however, there
were no significant differences between male patients with TRS
and non-TRS, as well as between female patients with TRS and
non-TRS.
Genotype Analysis
In male patients with schizophrenia, in the TRS group, COMT
rs4818 (χ2 = 1.333; df = 1; p = 0.248) and COMT rs4680
(χ2 = 0.929; df = 1; p = 0.335) genotypes distributions
did not deviate from HWE. In male patients who were not
treatment resistant (i.e., in non-TRS group), no departure
from HWE was found for COMT rs4818 (χ2 = 0.447;
df = 1; p = 0.503) and COMT rs4680 (χ2 = 1.492; df = 1;
p = 0.222) genotypes. In female TRS patients, no significant
deviation from HWE in COMT rs4818 (χ2 = 1.603; df = 1;
p = 0.206) and COMT rs4680 (χ2 = 0.197; df = 1;
p = 0.657) genotypes distributions was detected. Among
female patients in non-TRS group, frequencies of COMT
rs4818 (χ2 = 0.981; df = 1; p = 0.322) and COMT rs4680
(χ2 = 0.114; df = 1; p = 0.736) genotypes did not deviate from
HWE.
There were no significant differences in the frequency of the
genotypes or in the dominant or recessive model for the COMT
rs4818 and COMT rs4680 between male patients with or without
TRS (Table 2).
In female patients (Table 3) subdivided into TRS and non-
TRS groups, significant differences were found in the frequency
of the COMT rs4818 genotypes (CC, CG, and GG; p = 0.014)
and in the dominant model (C carriers, i.e., CC + CG vs.
GG; p = 0.008). The distribution of the genotypes in the
recessive model (G carriers, i.e., GG + GC vs. CC; p = 0.043)
for the COMT rs4818 did not differ significantly between
female TRS and non-TRS groups (Table 3). Further analysis
revealed that the C carriers were five times more likely to
be in the TRS group than GG homozygotes [odds ratio
(OR) (C carriers/GG) = 5.748; 95% confidence interval (CI)
(1.362–24.251), z = 2.381; p = 0.017] in female patients with
schizophrenia. Similar frequency of the COMT rs4680 genotypes
(GG, GA and AA), and the genotypes in the recessive (A
carriers, i.e., GA + AA vs. GG) or dominant (G carriers,
i.e., GG + GA vs. AA) model was found in female TRS
and non-TRS patients (Table 3). Although a difference in the
distribution of the G carriers vs. AA homozygotes was not
significant (p = 0.033) due to correction (p = 0.025), female
carriers of AA genotype of the COMT rs4680 were slightly
more frequent in TRS group than G carriers (R = 1.7; OR
(AA homozygotes/ G carriers) = 1.917, 95% CI (1.046–3.515);
z = 2.105; p = 0.035). These results showed that female AA
homozygotes had almost double chance to develop TRS when
compared to G carriers in female patients with schizophrenia
(Table 3).
Haplotype Analysis
To further examine the association of COMT rs4818 and
rs4680 polymorphisms with TRS in male and female patients,
a haplotype analysis was performed. As shown in Figure 1, a
high degree of linkage disequilibrium (D′ = 0.88) was revealed
for COMT rs4818 and rs4680 polymorphisms.
Table 4 shows the frequencies of the COMT (rs4818-rs4680)
haplotypes in all patients subdivided in TRS and non-TRS
group. The most common haplotype was C-A, followed by G-G
haplotype. There was a significant difference (p = 0.037) in
the distribution of G-G haplotype among TRS and non-TRS
patients, demonstrating that G-G haplotype was less frequently
represented in TRS than in non-TRS group (Table 4).
In the analysis of the COMT rs4818-rs4680 haplotypes, all
patients were subdivided into carriers and non-carriers of the
particular haplotype. For two of the most common haplotype (C-
A and G-G) groups, subjects were additionally subdivided into
“homozygotes” for the particular haplotype (carriers of the two
same haplotype groups), individuals that carry only one of the
examined haplotype, and non-carriers of the tested haplotype.
Because of the low frequency of the “homozygotes”, for another
two haplotype groups (C-G and G-A), patients were divided only
into carriers and non-carriers.
Haplotype analysis showed a lack of significant difference in
the frequency of the particular haplotypes between male TRS and
non-TRS patients (Table 5).
In female (Table 6) patients with schizophrenia, haplotype
distribution differed significantly between TRS and non-TRS
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TABLE 1 | The demographic and clinical data of male and female patients with schizophrenia subdivided in TRS and non-TRS groups.
TRS (N = 270) Non-TRS (N = 661)
Males (N = 215) Females (N = 55) Males (N = 330) Females (N = 331)
Age (years) (median, 25 and 75
percentile)
39 (30,45) 48 (38,58) 40 (31,49) 50 (39,57) H = 106.086; df = 3;
p < 0.001∗; Kruskal–Wallis
ANOVA
Smokers, N (%) 155 (72.09%) 27 (49.09%) 220 (66.67%) 172 (51.96%) χ2 = 198.8; df = 3;
p < 0.0001∗; χ2-test
PANSS total scores (median,
25 and 75 percentile)
130 (115,143) 106 (98,124) 105 (92,123) 90 (75,102) H = 324.222; df = 3;
p < 0.001∗; Kruskal–Wallis
ANOVA
PANSS positive scores
(median, 25 and 75 percentile)
34 (30,39) 28 (26,32) 26 (22,33) 22 (17,26) H = 300.511; df = 3;
p < 0.001∗; Kruskal–Wallis
ANOVA
PANSS negative scores
(median, 25 and 75 percentile)
34 (28,37) 27 (23,30) 26 (23,31) 23 (19,26) H = 248.191; df = 3;
p < 0.001∗; Kruskal–Wallis
ANOVA
PANSS general
psychopathology scores
(median, 25 and 75 percentile)
62 (56,69) 54 (48,63) 52 (45,59) 45 (38,51) H = 279.877; df = 3;
p < 0.001∗; Kruskal–Wallis
ANOVA
Chlorpromazine equivalent
doses, mg/per day (median, 25
and 75 percentile)
700 (500,1000) 500 (400,750) 500 (300,750) 400 (200,500) H = 136.508; df = 3;
p < 0.001∗; Kruskal–Wallis
ANOVA
Results are presented as medians with 25 and 75 percentile. N is the number of patients. ∗Significant differences between male and female TRS and non-TRS patients.
Non-TRS, non-treatment-resistant schizophrenia; PANSS, Positive and Negative Syndrome Scale; TRS, treatment-resistant schizophrenia.
TABLE 2 | The distribution of the COMT rs4818 and rs4680 genotypes in male patients with schizophrenia subdivided into TRS and non-TRS groups.
Male patients (N = 545) TRS (N = 215) Non-TRS (N = 330)
N Frequency (%) N Frequency (%)
COMT rs4818 genotypes CC 60 27.9 83 25.2 χ2 = 2.315; df = 2;
CG 99 46.0 171 51.8 p = 0.314; χ2-test
GG 56 26.0 76 23.0
C carriers C carriers 159 74.0 254 77.0 χ2 = 0.911; df = 1;
GG 56 26.0 76 23.0 p = 0.340; χ2-test
G carriers G carriers 155 72.1 247 74.8 χ2 = 0.671; df = 1;
CC 60 27.9 83 25.2 p = 0.413; χ2-test
COMT rs4680 genotypes AA 85 39.5 119 36.1 χ2 = 1.741; df = 2;
AG 95 44.2 167 50.6 p = 0.419; χ2-test
GG 35 16.3 44 13.3
A carriers A carriers 180 83.7 286 86.7 χ2 = 0.645; df = 1;
GG 35 16.3 44 13.3 p = 0.422; χ2-test
G carriers G carriers 130 60.5 211 63.9 χ2 = 0.511; df = 1;
AA 85 39.5 119 36.1 p = 0.475; χ2-test
Results are presented as numbers and %. N is the number of patients. COMT, catechol-O-methyl-transferase; C carriers of the COMT rs4818, the combined CC and CG
genotype; G carriers of the COMT rs4818, the combined GG and GC genotype; G carriers of the COMT rs4680, the combined GG and AG genotype; A carriers of the
COMT rs4680, the combined AA and AG genotype; non-TRS, non-treatment-resistant schizophrenia; TRS, treatment-resistant schizophrenia.
patients. Among female schizophrenia patients, haplotype G-G
was detected less frequently in TRS group (R = 1.5; p = 0.011)
compared to non-TRS group. Detailed analysis showed that
female non-carriers of the haplotype G-G were 2 times more
likely to be treatment resistant than female carriers of the
haplotype G-G (OR (non-carriers/GG carriers) = 2.1015; 95% CI
(1.179–3.743); z = 2.522; p = 0.012). Haplotype analysis confirmed
genotyping results since haplotype frequency of G-G/G-G, G-G/∗
and ∗/∗ haplotypes between female TRS and non-TRS patients
differed significantly (p = 0.009). Namely, presence of the G
allele was “protective” against TRS. The high activity G-G/G-G
haplotype was the rarest haplotype (3.6%) in female patients with
TRS, followed by G-G/∗∗ haplotype, while carriers of any other
haplotype than G-G were overrepresented (56.4%) in female
patients with TRS in comparison to non-TRS female patients
(Table 6).
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TABLE 3 | The distribution of the COMT rs4818 and rs4680 genotypes in female patients with schizophrenia subdivided into TRS and non-TRS group.
Female patients (N = 386) TRS (N = 55) Non-TRS (N = 331)
N Frequency (%) N Frequency (%)
COMT rs4818 genotypes CC 28 50.9 121 36.6 χ2 = 8.525; df = 2;
CG 25 45.5 151 45.6 p = 0.014∗; χ2- test
GG 2 3.6 59 17.8
C carriers C carriers 53 96.4 272 82.2 χ2 = 7.136; df = 1;
GG 2 3.6 59 17.8 p = 0.008∗; χ2-test
G carriers G carriers 27 49.1 210 63.4 χ2 = 4.100; df = 1;
CC 28 50.9 121 36.6 p = 0.043; χ2-test
COMT rs4680 genotypes AA 20 36.4 76 23.0 χ2 = 5.263; df = 2;
AG 25 45.5 162 48.9 p = 0.072; χ2-test
GG 10 18.2 93 28.1
A carriers A carriers 45 81.8 238 71.9 χ2 = 2.370; df = 1;
GG 10 18.2 93 28.1 p = 0.124; χ2-test
G carriers G carriers 35 63.6 255 77.0 χ2 = 4.534; df = 1;
AA 20 36.4 76 23.0 p = 0.033; χ2-test
Results are presented as numbers and %. N is the number of patients. ∗Significant difference in the distribution of the CC, CG, and GG genotypes; or of the C carriers and
GG homozygotes, between TRS and non-TRS patients. COMT, catechol-O-methyl-transferase; C carriers of the COMT rs4818, the combined CC and CG genotype; G
carriers of the COMT rs4818, the combined GG and GC genotype; G carriers of the COMT rs4680, the combined GG and AG genotype; A carriers of the COMT rs4680,
the combined AA and AG genotype; non-TRS, non-treatment-resistant schizophrenia; TRS, treatment-resistant schizophrenia.
FIGURE 1 | Linkage disequilibrium (LD) plot with D’ values characterizing
haplotype blocks in COMT gene. The plot was generated by Haploview 4.2
software. Block definition followed the rules of solid spine of LD. D’ values
multiplied by 100 are shown as a number in the diamonds.
DISCUSSION
Clinical Differences Between Patients
With TRS and Non-TRS
Our findings of four times higher prevalence of TRS in male
compared to female patients are in contrast to results from
Danish patients (Wimberley et al., 2017) who had higher
rates of TRS in female patients. However, this study used
different methodology, such as the determination of TRS by
a treatment-based proxy (Wimberley et al., 2017). In our study,
both male and female patients with TRS had significantly higher
PANSS total, positive, negative, and general psychopathology
scores, as well as higher chlorpromazine equivalent doses in
comparison to male and female patients in non-TRS group. This
is in agreement with previous studies reporting that patients with
TRS had more severe symptomatology as measured by PANSS
(Moretti et al., 2018) and received higher total antipsychotic dose
presented as chlorpromazine equivalents, compared to patients
with non-TRS (Hotta et al., 2011; de Bartolomeis et al., 2018;
Moretti et al., 2018). In the present study, the concentration of
antipsychotics in plasma was not measured. While about one-
third of patients with TRS had sub-therapeutic or non-detectable
antipsychotic plasma levels (McCutcheon et al., 2018), non-
adherence, or only partial adherence in some of our patients with
TRS cannot be ruled out. However, unlike the latter article which
excluded patients on long-acting antipsychotics (McCutcheon
et al., 2018), in the present study about a quarter of patients
received different depot antipsychotics (data not shown), which
provided continuous drug delivery. Furthermore, while the
majority of patients with TRS were hospitalized at the time of the
assessment, antipsychotic intake was monitored by hospital stuff.
Given the pronounced difference (an average of 100–200 mg/per
day) in chlorpromazine equivalents between individuals with
and without TRS, some of those patients might developed
the antipsychotic-induced dopamine suprasensitivity psychosis
(DSST). Although the presence of neurological disorders was
exclusion criteria, rating scales for the assessment of movement
disorders were not performed. Therefore, while subjects with
pronounced extrapyramidal symptoms or tardive dyskinesia
were not included, subtle movement disorders, indicative of
DSST (Chouinard et al., 2017), might have gone undetected
in some individuals. In the present study, the prevalence of
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TABLE 4 | The distribution of COMT rs4680-rs4818 haplotypes in all patients with schizophrenia subdivided into TRS and non-TRS group.
Haplotype All patients TRS, Non-TRS
Frequency (%) Frequency (%)
C-A 48.0 49.4, 47.4 χ2 = 0.585; p = 0.444; χ2-test
G-G 36.3 32.7, 37.8 χ2 = 4.436; p = 0.037∗; χ2-test
C-G 13.5 14.7, 13.0 χ2 = 1.019: p = 0.313; χ2-test
G-A 2.2 3.2, 1.8 χ2 = 3.422; p = 0.064; χ2-test
Results are presented as %. COMT, catechol-O-methyl-transferase; non-TRS, non-treatment-resistant schizophrenia; TRS, treatment-resistant schizophrenia. ∗Significant
differences in the frequency of G-G haplotype between TRS and non-TRS patients.
TABLE 5 | Haplotype frequencies of COMT rs4680 and rs4818 polymorphisms in male patients with schizophrenia subdivided according to the TRS.
Male patients (N = 565) TRS (N = 215) Non-TRS (N = 330)
N Frequency (%) N Frequency (%)
Haplotype C- A C-A/C-A 52 24.2 75 22.7 χ2 = 2.494; df = 2;
C-A/∗ 102 47.4 178 53.9 p = 0.287; χ2-test
∗/∗ 61 28.40 77 23.3
C-A carriers C-A carriers 154 71.6 253 76.7 χ2 = 1.748; df = 1;
Non-carriers 61 28.4 77 23.3 p = 0.186; χ2-test
Haplotype G-G G-G/ G-G 30 14.0 43 13.0 χ2 = 1.730; df = 2;
G-G/∗ 92 42.8 160 48.5 p = 0.421; χ2-test
∗/∗ 93 43.3 127 38.5
G-G carriers G-G carriers 122 56.7 203 61.5 χ2 = 1.231; df = 1;
Non-carriers 93 43.3 127 38.5 p = 0.267; χ2-test
C-G carriers C-G carriers 49 22.8 77 23.3 χ2 = 0.022; df = 1;
Non-carriers 166 77.2 253 76.7 p = 0.883; χ2-test
G-A carriers G-A carriers 12 5.6 9 2.7 χ2 = 2.862; df = 1;
Non-carriers 203 94.4 321 97.3 p = 0.091; χ2-test
∗Other haplotypes. Results are presented as numbers and %. N is the number of patients. COMT, catechol-O-methyl-transferase; non-TRS, non-treatment-resistant
schizophrenia; TRS, treatment-resistant schizophrenia.
TABLE 6 | Haplotype frequencies of COMT rs4680 and rs4818 polymorphisms in female patients with schizophrenia subdivided according to the TRS.
Female patients (N = 386) TRS (N = 55) Non-TRS (N = 331)
N Frequency (%) N Frequency (%)
Haplotype C-A C-A/C-A 17 30.9 71 21.5 χ2 = 4.198; df = 2;
C-A/∗ 28 50.9 161 48.6 p = 0.123; χ2-test
∗/∗ 10 18.2 99 29.9
C-A carriers C-A carriers 45 81.8 232 70.1 χ2 = 3.201; df = 1;
Non-carriers 10 18.2 99 29.9 p = 0.074; χ2-test
Haplotype G-G G-G/G-G 2 3.6 53 16.0 χ2 = 9.318; df = 2;
G-G/∗ 22 40.0 152 45.9 p = 0.009#; χ2-test
∗/∗ 31 56.4 126 38.1
G-G carriers G-G carriers 24 43.6 205 61.9 χ2 = 6.544; df = 1;
Non-carriers 31 56.4 126 38.1 p = 0.011#; χ2-test
C-G carriers C-G carriers 15 27.3 81 24.5 χ2 = 0.198; df = 1;
Non-carriers 40 72.7 250 75.5 p = 0.656; χ2-test
G-A carriers G-A carriers 3 5.5 8 2.4 χ2 = 1.572; df = 1;
Non-carriers 52 94.5 323 97.6 p = 0.210; χ2-test
∗Other haplotypes. Results are presented as numbers and %. N is the number of patients. COMT, catechol-O-methyl-transferase; non-TRS, non-treatment-resistant
schizophrenia; TRS, treatment-resistant schizophrenia. #Significant differences in the frequency of G-G/G-G, G-G/∗ and ∗/∗ haplotypes between TRS and non-TRS
patients.
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smoking was higher in males than females, in both patients
with TRS and non-TRS. This is in line with our previous data
showing higher prevalence of smoking in male (64%) than
in female (46%) patients with schizophrenia (Nikolac et al.,
2013), and agrees with the data from general population, given
that the men had higher smoking prevalence than woman in
European countries, including Croatia (Gallus et al., 2014).
Men with schizophrenia also had higher rates of nicotine
dependence and different smoking habits compared to healthy
men (Nikolac et al., 2013; Šagud et al., 2018). However, the
rate of smoking in our study was similar in patients with TRS
and non-TRS, which is consistent with the finding from the
smaller sample of 21 patients with TRS and 20 patients with
non-TRS (Mouchlianitis et al., 2016). Although patients with
schizophrenia have the highest known rates of smoking (de
Leon and Diaz, 2005), confirmed by the 62.8% of smokers
found in schizophrenia patients in our previous study (Nedic
Erjavec et al., 2017), our results suggest that treatment-resistance
does not further increase this rate. However, smoking might
be related to more severe clinical presentation in patients with
TRS, since smokers with TRS had higher PANSS total scores and
negative subscale scores, and performed significantly worse on
the problem solving cognitive task, compared to TRS patients
who did not smoke (Iasevoli et al., 2013). The relationship
between schizophrenia and smoking is complex (Šagud et al.,
2009) given that smoking status was also related to lower
total PANSS scores and the PANSS general psychopathology
scores in patients with schizophrenia (Nedic Erjavec et al.,
2017). Smoking might contribute to treatment resistance by
decreasing serum levels of clozapine and olanzapine, but the
dose increase might overcome those effects (Tsuda et al.,
2014).
Gender-Related Differences in the COMT
rs4680 and rs4818 Genotypic and
Haplotypic Association With Treatment
Resistance
Our results confirmed gender-related differences in the genotypic
and haplotypic association of the COMT rs4680 and rs4818 and
treatment resistance in patients with schizophrenia. Namely, our
study revealed that: (1) in male patients with schizophrenia,
there were no significant haplotypic and genotypic associations
between COMT rs4680 and rs4818 and treatment-resistance; (2)
in female patients with TRS, AA genotype carriers of the COMT
rs4680 were nominally more frequently present compared to
G carriers, whereas CC carriers of the COMT rs4818 were
significantly more frequent than G carriers; (3) in female patients
with TRS, the high activity G-G/G-G COMT haplotype was
rare, followed by G-G/∗∗ haplotype, while carriers of any other
than G-G haplotype were overrepresented, in comparison to
female patients with non-TRS. To the best of our knowledge,
this is the first report to document that the presence of high-
activity (G variants) of the COMT rs4680 and rs4818, and COMT
G-G/G-G haplotype, appears to be associated with lower risk
of TRS in female patients with schizophrenia, while no such
associations were observed in men. These findings suggest the
significant, but gender-specific associations of COMT variants
with the development of treatment-resistance in schizophrenia.
Gender-Related Association Between
the COMT rs4680 Genotype and
Treatment Resistance
Gender differences were previously noticed in COMT activity
(Chen et al., 2004) as well as in distribution of the COMT
rs4680 genotypes in healthy individuals (Gurvich and Rossell,
2015; El-Hage et al., 2017) and patients with schizophrenia
(Bollettini et al., 2017). There is also evidence of distinct, sex-
dependent brain changes related to COMT rs4680 polymorphism
(Bollettini et al., 2017; El-Hage et al., 2017). Female patients
with schizophrenia, carriers of the COMT rs4680 AA genotype,
had smaller volumes of caudate, putamen, and pallidum, while
male patients, homozygous for the Met allele showed higher or
similar subcortical volumes compared to other groups (Bollettini
et al., 2017). In healthy volunteers, male GG homozygotes had
higher white matter integrity compared to A carriers, whereas
no differences were observed in females (El-Hage et al., 2017).
In healthy women, carriers of the COMT rs4680 AA genotype
had reduced and GG genotype carriers had superior cognitive
flexibility, whereas in men no association with cognition was
found (Gurvich and Rossell, 2015). Those studies suggested that
AA homozygosity, specifically in women, might be adversely
associated with cognitive functioning (Gurvich and Rossell,
2015) and subcortical brain volumes (Bollettini et al., 2017),
which could be also related to the association of COMT rs4680
polymorphism with treatment-resistance observed only in female
patients with schizophrenia in the present study. On the other
hand, some studies have not observed associations of COMT
rs4680 polymorphism with age or gender (Walder et al., 2010;
Collip et al., 2011; Armbruster et al., 2012).
Four studies have addressed the association between COMT
rs4680 and TRS so far. Two of them have included only patients
with TRS (Bosia et al., 2015; Rajagopal et al., 2018) whereas
two other trials included patients with both TRS and non-TRS
(Inada et al., 2003; Terzic´ et al., 2016). The discrepancies across
the studies might arise from sex-differences, ethnic differences,
diversities in the populations studied, limited power and small
sample sizes, as well as different methodology such as the
various definitions of treatment-resistance and measurements of
psychopathology. In contrast to our results, TRS patients, carriers
of the AA or GA genotypes of the COMT rs4680, but who were
also carriers of one or two DRD4 120-bp alleles (120/240 and
120/120), experienced better response to clozapine than TRS
patients, carriers of the GG genotype (Rajagopal et al., 2018).
This study included 93 TRS patients of South Indian ethnicity,
but did not divide patients according to gender. Corresponding
to our results in male patients with schizophrenia, COMT rs4680
genotypes were not associated with better response to clozapine
in TRS (Rajagopal et al., 2018). Since in our study the presence
of the A allele was associated with TRS in female but not in
male patients, either different number of patients, the fact that
we did not evaluate gene-gene interaction with the DRD4 120-bp
alleles, or ethnic differences (Rajagopal et al., 2018), might explain
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these different results. In line with the results from the study
evaluating 107 treatment-resistant Italian patients (Bosia et al.,
2015), carriers of the COMT rs4680 GG genotype have shown
better response to clozapine (in reducing negative symptoms),
compared to patients with the GA and AA genotypes (Bosia et al.,
2015). In our study, this slight association was observed only in
female but not in male patients. Since the cited study (Bosia et al.,
2015) did not evaluate gender specific association with TRS, and
included much smaller sample, we might speculate that this non-
significant association (due to correction) of the AA genotype
with TRS might be presumably related to female gender. Our
results on the link between the AA genotype and TRS in female
patients with schizophrenia also agree with the data from the
100 Japanese patients with schizophrenia (Inada et al., 2003). In
this study, patients with TRS had marginally higher frequency
of the A variant of COMT rs4680 polymorphism, and the odds
ratio for the AA genotype in TRS was 4.392 (Inada et al., 2003).
Patients with the COMT rs4680 AA genotype also received higher
chlorpromazine equivalent doses compared to carriers of the GA
and GG genotypes (Inada et al., 2003). Although the sample size
was small (only eight patients had COMT rs4680 AA genotype),
and patients were not evaluated according to gender (Inada et al.,
2003), these results are in line with our female data. In agreement
with our data in males, but in contrast to data obtained in female
patients with or without TRS, no difference in the COMT rs4680
genotype frequency was detected in 138 patients: 44 treatment-
resistant and 94 treatment-responsive patients from Slovenia,
who were not divided by gender (Terzic´ et al., 2016).
Gender-Related Association Between the COMT
rs4818 Genotype and Treatment Resistance
While COMT rs4680 is among the most frequently investigated
polymorphisms in treatment response to psychotropic drugs,
only a few studies investigated COMT rs4818 polymorphism and
the response to antipsychotics (Gupta et al., 2009; Xu et al.,
2015; Shi et al., 2017). In our study the presence of the CC
genotype of the COMT rs4818 in female, but not in male group
of patients with TRS, was found significantly more frequently
than the presence of the GC and GG genotypes. In line with our
findings, in the large Shanghai cohort of 995 Chinese patients
with schizophrenia, C carriers of the COMT rs4818 had more
frequently poor response to quetiapine (Xu et al., 2015). The
association between COMT rs4818 and treatment response to
risperidone was also reported in 288 Shanghai patients with
schizophrenia (Shi et al., 2017), but opposed to our and their
previous (Xu et al., 2015) results, the G/C allele frequency was
similar between good and poor responders (Shi et al., 2017).
Gender-Related Association Between
the COMT rs4680 and rs4818 Haplotype
and TRS
The findings of the present study that carriers of the high activity
G-G/G-G haplotype were more frequently observed in non-TRS
female group, whereas female carriers of any other haplotype
than G-G were overrepresented in the group of patients with TRS,
suggest that presence of the G allele might be associated with
decreased risk of TRS. This association was also confirmed in
Shanghai cohort (Xu et al., 2015). In contrast to our data, among
117 patients with schizophrenia of the southern Indian origin,
the COMT haplotype C-A (rs4818-r4680) was observed more
often in responders to risperidone, compared to non-responders
(Gupta et al., 2009). However, these data were not analyzed
by gender, and the treatment-response was defined only by the
clinical global impression scale (Gupta et al., 2009).
Our results showed that presence of the high activity (i.e., G
variants) of the COMT was associated with lower risk of TRS in
female patients. Likewise, negative symptoms of schizophrenia
were less severe in female patients carrying the high activity
COMT variants (rs740603 (G)-rs4818 (G) haplotype), but this
effect was not observed in male patients with schizophrenia (Li
et al., 2012). If this finding will be confirmed in larger studies and
meta-analyses, women with schizophrenia who are carriers of the
COMT rs4680 and rs4818 low-activity haplotypes, might require
different treatment approach, such as early clozapine initiation
(Siskind et al., 2017), clozapine augmentation with different
antiepileptic drugs (Zheng et al., 2017), or electroconvulsive
therapy (ECT) (Vuksan et al., 2018).
The Association Between the
High-Activity COMT Haplotype and
Treatment Response in Female Patients
With Schizophrenia: Possible
Explanations
COMT activity plays a key role in the regulation of dopamine
activity in PFC, while its role in the regulation of striatal
dopamine turnover is less important due to higher abundance
of dopamine transporter in this region (Bilder et al., 2004). In
line with this hypothesis, in healthy subjects, COMT rs4680 GG
carriers had lower dopamine tone in cortical and limbic regions,
compared to carriers of the GA or AA genotypes, while no
changes of dopamine tone were detected in the striatal regions
(Slifstein et al., 2008). However, striatal dopamine turnover seems
to be altered in patients with TRS (Kim et al., 2017). While
patients with schizophrenia generally exhibited elevated striatal
dopamine synthesis capacity compared to healthy controls
(Fusar-Poli and Meyer-Lindenberg, 2013), individuals suffering
from TRS had lower capacity of dopamine synthesis in striatum
(Kim et al., 2017). This finding was observed in TRS patients
treated with clozapine (Kim et al., 2017) and in patients treated
with other antipsychotics (Demjaha et al., 2012), in comparison
to patients who responded to antipsychotic treatment. Although
COMT has a minor role in metabolizing striatal dopamine,
modifications of COMT activity may affect dopamine signaling
also in the striatum, as shown by the data from animal models
(Simpson et al., 2014; Tammimaki et al., 2016), and from
some (Boot et al., 2011) but not all (Slifstein et al., 2008)
human reports. Considering that compensatory mechanisms
might influence dopamine function in striatum (Simpson et al.,
2014), the relationship between prefrontal dopamine availability,
modulated by COMT rs4680, and striatal dopamine tone (Bilder
et al., 2004; Ceaser et al., 2013) was proposed. In post-mortem
brain samples of individuals without psychiatric disorders,
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carriers of the COMT rs4680 GG genotype had greater expression
of tyrosine hydroxylase mRNA in mesencephalic dopamine
neurons than GA genotype carriers, particularly in neuronal
populations that project to the striatum, suggesting higher
dopamine synthesis in striatal regions of GG homozygotes (Akil
et al., 2003).
Although these studies did not account the possible gender
differences (Akil et al., 2003; Slifstein et al., 2008), we might
speculate that females with AA genotype of the COMT rs4680
might have had higher prefrontal and compensatory lower
striatal dopamine levels, which were reported in patients with
TRS (Kim et al., 2017). The dopamine synthesis capacity in
striatum was proposed as a biomarker for TRS (Kim et al., 2017).
In the presence of higher dopamine stimulation from PFC, such
as in the COMT rs4680 AA homozygous subjects, dopamine
release might decrease in striatum in an attempt to protect
the brain from excessive dopaminergic stimulation, and this
mechanism might be related to treatment-resistance. According
to our findings, this hypothesis might be only relevant for
female patients with schizophrenia. Given the COMT-inhibiting
properties of estradiol (McDermott et al., 2015), decreased
COMT activity in women (Chen et al., 2004), and large sex-
differences in dopaminergic cortical pathways in preclinical
model (Kritzer and Creutz, 2008), it could be hypothesized that
women have higher PFC dopamine levels than men, carrying the
same COMT genotype. Such greater dopaminergic stimulation
in females could lead to a gender-specific hyperdopaminergic
overdrive in PFC, and consequently to decreased dopamine
levels in striatum, which might eventually predispose women to
TRS. This proposal fits the presumption that some patients do
not respond to treatment because they do not exhibit elevated
dopamine input in striatum (Demjaha et al., 2012; Kim et al.,
2017), while increased dopamine stimulation in striatum is the
target for antipsychotic drugs (Fusar-Poli and Meyer-Lindenberg,
2013). However, the current study did not measure dopamine
levels.
The evidence of sexual dimorphism of COMT gene is
still inconclusive, but continues to accumulate (Harrison
and Tunbridge, 2008). The findings regarding sex-dependent
associations of COMT with various clinical and biological
features have been reported in diverse populations (Rybakowski
et al., 2006; Lang et al., 2007; Chen C. et al., 2011; Jacobs and
D’Esposito, 2011; Klebe et al., 2013; Koike et al., 2018), as well as
in preclinical trials (Gogos et al., 1998; Laatikainen et al., 2013;
Sannino et al., 2015). In general, sexually dimorphic effects of
COMT gene variations are complex, and range from robust to
subtle, depending on the parameters, which were measured.
Great amount of the data demonstrating gender differences
in association of COMT gene with various personality traits,
phenotypes, cognitive domains and behaviors, came from studies
that enrolled healthy individuals (Eley et al., 2003; Enoch et al.,
2003; Olsson et al., 2005; Stein et al., 2005; Kim et al., 2006;
Barnett et al., 2007; Lang et al., 2007; de Castro-Catala et al., 2015;
Costa et al., 2016). However, sexual dimorphism of COMT gene
has been also reported in various neuropsychiatric disorders such
as anxiety disorders, depression, attention deficit hyperactivity
disorder, and obsessive-compulsive disorder (Karayiorgou et al.,
1997, 1999; Domschke et al., 2004, 2007; Poyurovsky et al., 2005;
Denys et al., 2006; Rothe et al., 2006; Pooley et al., 2007; Cao
et al., 2014; Akutagava-Martins et al., 2016). In addition, our
results are in line with other studies demonstrating sex-specific
associations of COMT variants in patients with schizophrenia
(Shifman et al., 2002; Dempster et al., 2006; Rybakowski et al.,
2006; Lee and Kim, 2011). All these data suggest that COMT
gene variations might contribute to the sex differences in brain
function and structure (Domschke et al., 2012; White et al., 2014;
Sannino et al., 2015, 2017; Elton et al., 2017), and consequently
result in sexual dimorphism in the predisposition to various
neuropsychiatric disorders. Sex-specific effects of COMT gene
are usually attributed to transcriptional regulation by estrogens,
and it has been suggested that reciprocal and partly genotype-
influenced interactions between COMT and estrogens may
be relevant to sexual dimorphism (Harrison and Tunbridge,
2008). Although the biological reason why COMT association
is sex-specific is still not clear, it has been hypothesized
that COMT genotype may modulate the role of estrogens in
brain function and dysfunction (Seeman, 1997), while estrogens
affect COMT activity and its pathophysiological consequences
by influencing the COMT gene expression (Harrison and
Tunbridge, 2008). However, additional mechanisms are also
possible. Nevertheless, it is known from various studies that
sex differences in the genetic architecture of many human traits
and psychiatric disorders are common. Namely, in addition to
COMT, sexually dimorphic genetic associations with psychiatric
phenotypes have been reported also for other autosomal genes
such as HTR2A (Enoch et al., 2001), MTHFR (Sazci et al.,
2005; Kempisty et al., 2006), and AC7 (Hines et al., 2006).
Therefore, our findings reporting sex-specific associations of
COMT variants with the development of treatment-resistance
in schizophrenia also contribute to the knowledge in this
field.
Limitations of the Study
Limitation of the study is the fact that treatment-resistance in
schizophrenia patients was determined retrospectively. Another
limitation of this investigation is the lower number of female
then male patients, which resulted in a limited representation
of some of the genotypes after the gender-stratified analysis was
conducted. Therefore, the obtained results require replication in
a larger sample.
CONCLUSION
Our findings reveal complex and gender-dependent genotypic
and haplotypic associations between COMT rs4680 and rs4818
and TRS. In males with schizophrenia, treatment-resistance was
not associated with the COMT rs4818 and rs4680 genotypes
or haplotypes. In contrast, as far as we are aware, this is the
first study to show that in female patients with schizophrenia,
the presence of high-activity (G variants) of the COMT rs4680
and rs4818 polymorphisms, and the presence of the G-G/G-G
haplotype, is associated with the lower risk of TRS. These findings
extend previously reported gender-related association of COMT
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rs4680 variants and TRS, and for the first time detect gender-
dependent association of COMT rs4818 polymorphism with
treatment-resistance in patients with schizophrenia. Accordingly,
we might speculate that determination of the COMT rs4680 and
rs4818 genotypes and haplotypes early in the course of treatment
might help in the prediction of the treatment-resistance in
female patients with schizophrenia. However, those findings
must be interpreted with caution, given that the number of
included females was substantially lower than the number of
males. Therefore, investigation of the genotypic and haplotypic
association between COMT SNPs rs4680 and rs4818 and TRS in
the larger sample of females with schizophrenia is warranted.
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